Ikena Oncology Stock Probability Of Bankruptcy

IKNA Stock  USD 1.44  0.05  3.60%   
Ikena Oncology's chance of distress is over 50% at this time. It has a moderate odds of going through some financial crisis in the next 2 years. Chance Of Bankruptcy shows the probability of financial distress over the next two years of operations under current economic and market conditions. All items used in analyzing the odds of distress are taken from the Ikena balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Ikena Oncology Piotroski F Score and Ikena Oncology Altman Z Score analysis.
For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.
  

Ikena Probability Of Bankruptcy Analysis

Ikena Oncology's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
 2021 2022 2023 2024 (projected)
Total Operating Expenses65.1M86.5M83.6M70.7M
Cost Of Revenue47.1M2.0M1.0M969K

Probability Of Bankruptcy

 = 

Normalized

Z-Score

More About Probability Of Bankruptcy | All Equity Analysis

Current Ikena Oncology Probability Of Bankruptcy

    
  Over 56%  
Most of Ikena Oncology's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ikena Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Ikena Oncology probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Ikena Oncology odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Ikena Oncology financial health.
Is Ikena Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.63)
Revenue Per Share
0.219
Quarterly Revenue Growth
(0.88)
Return On Assets
(0.26)
Return On Equity
(0.43)
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Ikena Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Ikena Oncology is extremely important. It helps to project a fair market value of Ikena Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Ikena Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Ikena Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Ikena Oncology's interrelated accounts and indicators.
0.260.8-0.910.020.650.910.650.970.90.82-0.78-0.770.91-0.60.820.90.9-0.260.90.65
0.26-0.08-0.17-0.810.320.45-0.440.160.24-0.02-0.03-0.340.030.24-0.020.030.24-0.480.030.03
0.8-0.08-0.860.120.570.780.850.850.851.0-0.82-0.650.96-0.931.00.950.850.120.890.66
-0.91-0.17-0.860.05-0.86-0.8-0.69-0.91-0.82-0.880.970.63-0.910.75-0.88-0.91-0.820.0-0.93-0.86
0.02-0.810.120.05-0.22-0.120.370.00.10.080.02-0.120.05-0.050.080.040.1-0.050.0-0.05
0.650.320.57-0.86-0.220.590.380.630.570.59-0.89-0.470.61-0.480.590.630.590.060.660.92
0.910.450.78-0.8-0.120.590.480.860.970.81-0.64-0.920.83-0.520.810.820.97-0.390.740.5
0.65-0.440.85-0.690.370.380.480.780.60.83-0.71-0.370.86-0.860.830.870.60.430.850.66
0.970.160.85-0.910.00.630.860.780.850.86-0.81-0.680.96-0.710.860.960.86-0.040.970.71
0.90.240.85-0.820.10.570.970.60.850.87-0.67-0.950.86-0.60.870.861.0-0.340.760.53
0.82-0.021.0-0.880.080.590.810.830.860.87-0.83-0.680.96-0.921.00.960.870.090.890.66
-0.78-0.03-0.820.970.02-0.89-0.64-0.71-0.81-0.67-0.830.45-0.840.79-0.83-0.85-0.68-0.2-0.88-0.93
-0.77-0.34-0.650.63-0.12-0.47-0.92-0.37-0.68-0.95-0.680.45-0.670.33-0.68-0.66-0.940.51-0.52-0.36
0.910.030.96-0.910.050.610.830.860.960.860.96-0.84-0.67-0.860.961.00.870.10.970.72
-0.60.24-0.930.75-0.05-0.48-0.52-0.86-0.71-0.6-0.920.790.33-0.86-0.92-0.86-0.6-0.43-0.84-0.64
0.82-0.021.0-0.880.080.590.810.830.860.871.0-0.83-0.680.96-0.920.960.870.090.890.66
0.90.030.95-0.910.040.630.820.870.960.860.96-0.85-0.661.0-0.860.960.860.120.970.75
0.90.240.85-0.820.10.590.970.60.861.00.87-0.68-0.940.87-0.60.870.86-0.320.770.55
-0.26-0.480.120.0-0.050.06-0.390.43-0.04-0.340.09-0.20.510.1-0.430.090.12-0.320.160.36
0.90.030.89-0.930.00.660.740.850.970.760.89-0.88-0.520.97-0.840.890.970.770.160.78
0.650.030.66-0.86-0.050.920.50.660.710.530.66-0.93-0.360.72-0.640.660.750.550.360.78
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Competition

Based on the latest financial disclosure, Ikena Oncology has a Probability Of Bankruptcy of 56%. This is 29.36% higher than that of the Biotechnology sector and 2.12% higher than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 40.6% lower than that of the firm.

Ikena Probability Of Bankruptcy Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ikena Oncology's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ikena Oncology could also be used in its relative valuation, which is a method of valuing Ikena Oncology by comparing valuation metrics of similar companies.
Ikena Oncology is currently under evaluation in probability of bankruptcy category among related companies.

Ikena Oncology Main Bankruptcy Drivers

201920202021202220232024 (projected)
Total Current Liabilities24.3M28.3M27.2M21.5M14.2M21.9M
Total Current Assets85.2M166.0M236.5M160.0M178.7M155.2M
Total Cash From Operating Activities47.9M(37.8M)(60.3M)(74.1M)(79.7M)(75.8M)

Ikena Fundamentals

About Ikena Oncology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Ikena Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ikena Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ikena Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 79 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Ikena Oncology in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Ikena Oncology's short interest history, or implied volatility extrapolated from Ikena Oncology options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Ikena Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ikena Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ikena Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ikena Oncology Stock:
Check out Ikena Oncology Piotroski F Score and Ikena Oncology Altman Z Score analysis.
For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.
You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for Ikena Stock analysis

When running Ikena Oncology's price analysis, check to measure Ikena Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ikena Oncology is operating at the current time. Most of Ikena Oncology's value examination focuses on studying past and present price action to predict the probability of Ikena Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ikena Oncology's price. Additionally, you may evaluate how the addition of Ikena Oncology to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Is Ikena Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.63)
Revenue Per Share
0.219
Quarterly Revenue Growth
(0.88)
Return On Assets
(0.26)
Return On Equity
(0.43)
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.